HC Wainwright Reiterates Neutral Rating for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports.

GERN has been the topic of a number of other reports. Scotiabank reduced their target price on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. Stifel Nicolaus reduced their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Geron in a research report on Wednesday. Barclays reiterated an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. Finally, B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.68.

Geron Stock Down 5.6 %

Shares of GERN opened at $1.67 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52 week low of $1.46 and a 52 week high of $5.34. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.22 and a beta of 0.53. The stock has a fifty day moving average of $2.66 and a 200-day moving average of $3.61.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The firm had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. As a group, sell-side analysts anticipate that Geron will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Geron

A number of hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP acquired a new position in shares of Geron during the third quarter valued at about $200,268,000. Holocene Advisors LP purchased a new stake in shares of Geron during the 3rd quarter valued at $82,498,000. Janus Henderson Group PLC boosted its stake in Geron by 140.0% in the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after acquiring an additional 13,163,889 shares during the last quarter. Vestal Point Capital LP increased its position in Geron by 947.6% in the fourth quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock worth $38,940,000 after buying an additional 9,950,000 shares during the last quarter. Finally, Braidwell LP purchased a new stake in Geron in the 4th quarter worth about $24,802,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.